CORSICANA, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Birchtech Corp. (NYSE American: BCHT) (TSX: BCHT) (“Birchtech” or the “Company”), a leader in specialty activated carbon technologies for sustainable air and water treatment, today announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock at a public offering price of $2.40 per share, before deducting underwriting discounts and commissions and offering expenses, for aggregate gross proceeds of approximately $15.0 mill ...

Core Viewpoint - Birchtech Corp. is set to uplist its common stock to the NYSE American, enhancing its visibility and liquidity in the capital markets, with trading expected to begin around February 12, 2026 [1][4]. Group 1: Listing Details - The common stock of Birchtech is currently traded on the Toronto Stock Exchange (TSX) and the OTCQB market, and it will continue to trade on the OTCQB until the NYSE American listing is effective [3]. - The approval of the NYSE American listing is a condition for the concurrent offering of common stock, which is subject to market conditions and regulatory approval [2]. Group 2: Company Overview - Birchtech Corp. specializes in activated carbon technologies aimed at sustainable air and water treatment, focusing on innovative solutions for mercury emissions and water purification, particularly targeting forever chemicals like PFAS and PFOS [6]. - The company aims to drive sustainable growth by converting utilities into long-term licensees and supply customers while accelerating the rollout of its next-generation water purification platform [4].

Core Insights - Moleaer partners with Xylem Inc. to scale nanobubble technology for wastewater treatment globally, indicating a significant advancement in water treatment innovation [1][9] - The partnership includes a global distribution agreement and strategic investment, enhancing Moleaer's market presence [1] Technology and Performance - Nanobubble technology has been successfully deployed in various wastewater treatment facilities, notably at the Maple Creek Wastewater Treatment Plant, leading to reduced chemical costs and improved compliance with discharge permits [2][6] - Nanobubbles, which are 2,500 times smaller than a grain of salt, enhance gas transfer efficiency and accelerate various treatment processes without requiring infrastructure upgrades [3][8] Cost Savings and Efficiency - Moleaer's technology has demonstrated significant operational savings, including a 6.8% increase in biogas production, a 5.3% reduction in electricity use, and an 84% reduction in chemical use at a facility in Denmark [6] - The integration of nanobubbles in wastewater treatment plants results in lower energy and chemical usage, increased treatment capacity, and measurable performance gains with minimal disruption [5][6] Market Impact and Future Prospects - The partnership is expected to set a new standard in sustainable water treatment, leveraging Xylem's global reach and Moleaer's expertise in nanobubble technology [9] - Moleaer's proven track record with over 4,000 installations worldwide across various sectors underscores the technology's versatility and effectiveness [4][11]

Core Viewpoint - Growth stocks are appealing due to their potential for above-average financial growth, but identifying stocks that can fulfill their growth potential is challenging [1] Group 1: Company Overview - Xylem (XYL) is highlighted as a recommended growth stock with a favorable Growth Score and a top Zacks Rank [2] - The company operates in the water and wastewater treatment sector, which is currently positioned for growth [3] Group 2: Earnings Growth - Xylem has a historical EPS growth rate of 15%, with projected EPS growth of 9.2% this year, surpassing the industry average of 7.7% [4] - Double-digit earnings growth is preferred by growth investors as it indicates strong future prospects [3] Group 3: Cash Flow Growth - Xylem's year-over-year cash flow growth is 27.1%, significantly higher than the industry average of 8.8% [5] - The company's annualized cash flow growth rate over the past 3-5 years is 11%, compared to the industry average of 10.4% [6] Group 4: Earnings Estimate Revisions - There has been a positive trend in earnings estimate revisions for Xylem, with a 0.2% increase in the Zacks Consensus Estimate for the current year over the past month [7] Group 5: Investment Positioning - Xylem has earned a Growth Score of B and a Zacks Rank 2 due to positive earnings estimate revisions, positioning it well for potential outperformance [9]